

Clinical trials of exenatide 20g

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
exenatide 20g vs glibenclamide			
Derosa , 2010 n=63/65 follow-up:	exenatide 10 microg twice a day versus glibenclamide 5 mg three times a day	patients with uncontrolled type 2 diabetes mellitus receiving therapy with metformin	
exenatide 20g/d vs placebo			
Apoian , 2010 n=96/98 follow-up: 24 weeks	10 microg exenatide twice daily injection + lifestyle modification program versus placebo + lifestyle modification program	overweight or obese participants with type 2 diabetes treated with metformin and/or sulfonylurea	Parallel groups double-blind
H8O-MC-GWBJ, 9698, 20g/d , 2008 <i>unpublished</i> n=78/78 follow-up: 24 weeks	exenatide twice daily 10 g for 24 weeks versus placebo	Drug-Naive Patients with Type 2 Diabetes and inadequate glycemic control through diet and exercise	Parallel groups double-blind 4 countries
exenatide 20g/d vs placebo (add on insulin)			
Buse , 2011 [NCT00765817] n=138/123 follow-up: 30 weeks	twice-daily 10 g exenatide injections versus placebo (on top insulin glargine)	Adults with type 2 diabetes and an HbA1c level of 7.1% to 10.5% who were receiving insulin glargine alone or in combination with metformin or pioglitazone (or both agents)	Parallel groups double-blind Greece, Israel, Mexico, United Kingdom, USA
exenatide 20g/d vs placebo (add on MET)			
DeFronzo 20g/d , 2005 [NCT00039013] n=NA follow-up: 30 weeks	Exenatide 1020 g daily versus Placebo on-top of Metformin	patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses	Parallel groups double blind USA
exenatide 20g/d vs placebo (add on MET+/-SU)			
Gao , 2009 [NCT00324363] n=234/232 follow-up: 16 weeks	exenatide 5 mg then 10 mg twice-daily for 4 and 12 weeks versus placebo	Asian descent with type 2 diabetes and inadequate glycemic control taking metformin alone or Met and sulfonylureas	Parallel groups double-blind 4 countries
exenatide 20g/d vs placebo (add on SU)			

continued...

Trial	Treatments	Patients	Trials design and methods
Buse 20g/d , 2004 n=129/123 follow-up: 30 weeks	Exenatide 10g twice daily versus Placebo on-top of SU	patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy	double blind (not adequate) US
exenatide 20g/d vs placebo (add on SU+MET)			
Kendall 20g/d , 2005 [NCT00035984] n=241/247 follow-up: 30 weeks	Exenatide 10 g bid versus Placebo on-top of sulphonylureas+metformin	patients with type 2 diabetes unable to achieve glyceimic control with metformin-sulfonylurea combination therapy	Parallel groups double blind USA
exenatide 20g/d vs placebo (add on TZD+/-MET)			
Zinman 20g/j , 2007 [NCT00099320] n=121/112 follow-up: 16 weeks	Exenatide 20 g daily versus Placebo on-top of thiazolidinediones+/-metformin	patients with type 2 diabetes that was suboptimally controlled with TZD treatment (with or without metformin)	double blind Canada, Spain, and the United States
Zinman 20g/j A MODIFIER , 2007 n=121/112 follow-up: 16 weeks	exenatide Subcutaneous abdominal injections of 10 microg twice daily versus placebo	patients with type 2 diabetes that was suboptimally controlled with TZD treatment (with or without metformin)	Parallel groups double-blind Canada, Spain, and the United States
exenatide 20g/d vs BIAsp 30 daily			
Bergenstal (once daily) , 2009 n=NA follow-up: 24 weeks	exenatide(5 microg BID for 4 weeks and 10 microg BID thereafter) versus biphasic insulin aspart 70/30 (BIAsp 30) 30 QD (12 U before supper)	subjects with type 2 diabetes mellitus insulin naive, not achieving glyceimic targets with metformin and sulfonylurea	Parallel groups open
exenatide 20g/d vs BIAsp 30 twice daily			
Bergenstal (twice daily) , 2009 n=NA follow-up:	exenatide (5 microg BID for 4 weeks and 10 microg BID thereafter) versus biphasic insulin aspart 70/30 (BIAsp 30) 30 BID (12 U divided equally between pre-breakfast and pre-supper)	subjects with type 2 diabetes mellitus insulin naive, not achieving glyceimic targets with metformin and sulfonylurea	Parallel groups open
exenatide 20g/d vs insulin (add on SU+MET)			
Heine , 2005 n=282/267 follow-up: 26 weeks	Exenatide 20 g daily versus Insulin on-top of sulphonylureas+metformin	-	open
exenatide 20g/d vs insulin (add on SU/MET)			

continued...

Trial	Treatments	Patients	Trials design and methods
Barnett , 2007 [NCT00099619] n=136/127 follow-up: 16 weeks	Exenatide 20 g daily versus Insulin	patients with type 2 diabetes	Cross over open Australia, Greece,Hungary, Italy, Mexico, and Poland
Davis , 2007 [NCT00099333] n=33/16 follow-up: 16 weeks	Exenatide 20 g daily versus Insulin on-top of sulphonylureas/metformin	patients with type 2 diabetes using insulin in combination with oral antidiabetes agents	Parallel groups open USA
exenatide 20g/d vs insulin BIAsp twice daily add on SU+MET			
Nauck , 2007 [NCT00082407] n=253/248 follow-up: 52 weeks	Exenatide 20 g daily versus Insulin on-top of sulphonylureas+metformin	patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin	Parallel groups open 13 countries
exenatide 20g/d vs insulin glargine (add on MET)			
Bunck , 2009 [NCT00097500] n=36/33 follow-up: 52 weeks	exenatide 10g bid versus insulin glargine	metformin-treated patients with type 2 diabetes	Parallel groups
exenatide 20g/d vs rosiglitazone add on MET			
DeFronzo (EXE vs ROSI) , 2010 n=45/45 follow-up: 20 weeks	EXE 10 microg b.i.d. versus ROSI 4 mg b.i.d.	subjects with type 2 diabetes on metformin	Parallel groups open
exenatide 20g/d vs sitagliptin (add on MET)			
DeFronzo , 2008 [NCT00477581] n=NA follow-up: 2 weeks	exenatide subcutaneous injection versus sitagliptin (100 mg QAM) for 2 weeks	metformin-treated T2D patients	Cross over double-blind USA
exenatide 20g/d vs weekly exenatide			
Drucker , 2008 [NCT00308139] n=NA follow-up: 30 weeks	10 mug exenatide administered twice a day versus long-acting release formulation of exenatide 2 mg administered once weekly	patients with type 2 diabetes naive to drug therapy, or on one or more oral antidiabetic agents	Parallel groups open

More details and results :

- insulin secretagogues peptides (incretins) for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q381>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/>

go-Q509

- antidiabetic drugs for diabetes type 2 in Patients inadequately controlled on MET+SU therapy at <http://www.trialresultscenter.org/go-Q510>
- antidiabetic drugs for diabetes type 2 in patients with insufficient glycaemic control with bitherapy at <http://www.trialresultscenter.org/go-Q511>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled with insulin at <http://www.trialresultscenter.org/go-Q513>

References

Derosa, 2010:

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF Exenatide versus glibenclamide in patients with diabetes. *Diabetes Technol Ther* 2010;12:233-40 [20151774] [10.1089/dia.2009.0141](https://doi.org/10.1089/dia.2009.0141)

Apovian, 2010:

Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, Glass LC Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. *Am J Med* 2010;123:468.e9-17 [20399326] [10.1016/j.amjmed.2009.11.019](https://doi.org/10.1016/j.amjmed.2009.11.019)

H8O-MC-GWBJ, 9698, 20g/d, 2008:

unpublished

Buse, 2011:

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. *Ann Intern Med* 2011 Jan 18;154:103-12 [21138825] [10.1059/0003-4819-154-2-201101180-00300](https://doi.org/10.1059/0003-4819-154-2-201101180-00300)

DeFronzo 20g/d, 2005:

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2005;28:1092-100 [15855572]

Gao, 2009:

Gao Y, Yoon KH, Chuang LM, Mohan V, Ning G, Shah S, Jang HC, Wu TJ, Johns D, Northrup J, Brodows R Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. *Diabetes Res Clin Pract* 2009;83:69-76 [19019476] [10.1016/j.diabres.2008.09.037](https://doi.org/10.1016/j.diabres.2008.09.037)

Buse 20g/d, 2004:

Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care* 2004;27:2628-35 [15504997]

Kendall 20g/d, 2005:

Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulphonylurea. *Diabetes Care* 2005;28:1083-91 [15855571]

Zinman 20g/j, 2007:

Zinman B, Hoogwerf BJ, Durn Garca S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2007;146:477-85 [[17404349](#)]

Zinman 20g/j A MODIFIER, 2007:

Zinman B, Hoogwerf BJ, Durn Garca S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2007;146:477-85 [[17404349](#)]

Bergental (once daily), 2009:

Bergental R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. *Curr Med Res Opin* 2009;25:65-75 [[19210140](#)] [10.1185/03007990802597951](#)

Bergental (twice daily), 2009:

Bergental R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. *Curr Med Res Opin* 2009;25:65-75 [[19210140](#)] [10.1185/03007990802597951](#)

Heine, 2005:

Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widell MH, Brodows RG Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 2005;143:559-69 [[16230722](#)]

Barnett, 2007:

Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. *Clin Ther* 2007;29:2333-48 [[18158075](#)] [10.1016/j.clinthera.2007.11.006](#)

Davis, 2007:

Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. *Diabetes Care* 2007;30:2767-72 [[17595353](#)] [10.2337/dc06-2532](#)

Nauck, 2007:

Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. *Diabetologia* 2007;50:259-67 [[17160407](#)] [10.1007/s00125-006-0510-2](#)

Bunck, 2009:

Bunck MC, Diamant M, Cornr A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Jrvinen H, Heine RJ One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. *Diabetes Care* 2009;32:762-8 [[19196887](#)] [10.2337/dc08-1797](#)

Bunck MC, Cornr A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Jrvinen H, Diamant M Effects of exenatide on measures of β -cell function after 3 years in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2011;34:2041-7 [[21868779](#)] [10.2337/dc11-0291](#)

Bunck MC, Cornr A, Eliasson B, Heine RJ, Shaginian RM, Wu Y, Yan P, Smith U, Yki-Jrvinen H, Diamant M, Taskinen MR One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. *Atherosclerosis* 2010;212:223-9 [[20494360](#)] [10.1016/j.atherosclerosis.2010.04.024](#)

DeFronzo (EXE vs ROSI), 2010:

DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. *Diabetes Care* 2010;33:951-7 [[20107105](#)] [10.2337/dc09-1521](#)

DeFronzo, 2008:

DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. *Curr Med Res Opin* 2008;24:2943-52 [[18786299](#)] [10.1185/03007990802418851](#)

Drucker, 2008:

Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. *Lancet* 2008 Oct 4;372:1240-50 [[18782641](#)]

Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K, Trautmann M, Shen LZ, Porter LE DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. *Diabetes Care* 2010;33:1255-61 [[20215461](#)] [10.2337/dc09-1914](#)

Entry terms: exenatide, exenatide, bydureon, exendin-4, Ex4 peptide, exendin 4, AC 2993 LAR, Byetta, AC 2993,